Preclinical lead optimization of a 1,2,4-triazole based tankyrase inhibitor

Tools

Item Type:	Article
Title:	Preclinical lead optimization of a 1,2,4-triazole based tankyrase inhibitor
Creators Name:	Waaler, J., Leenders, R., Sowa, S.T., Alam Brinch, S., Lycke, M., Nieczypor, P., Aertssen, S., Murthy, S., Galera-Prat, A., Damen, E., Wegert, A., Nazare, M., Lehtiö, L. and Krauss, S.
Abstract:	Tankyrases 1 and 2 are central biotargets in the WNT/β-catenin signaling and Hippo signaling pathways. We have previously developed tankyrase inhibitors bearing a 1,2,4-triazole moiety and binding predominantly to the adenosine binding site of the tankyrase catalytic domain. Here we describe a systematic structure-guided lead optimization approach of these tankyrase inhibitors. The central 1,2,4-triazole template and trans-cyclobutyl linker of the lead compound 1 were left unchanged, while side-group East, West, and South moieties were altered by introducing different building blocks defined as point mutations. The systematic study provided a novel series of compounds reaching picomolar IC(50) inhibition in WNT/β-catenin signaling cellular reporter assay. The novel optimized lead 13 resolves previous atropisomerism, solubility, and Caco-2 efflux liabilities. 13 shows a favorable ADME profile, including improved Caco-2 permeability and oral bioavailability in mice, and exhibits antiproliferative efficacy in the colon cancer cell line COLO 320DM in vitro.
Keywords:	Biological Availability, Caco-2 Cells, Cell Proliferation, Drug Design, Poly(ADP-ribose) Polymerase Inhibitors, Solubility, Tankyrases, Triazoles, Animals, Mice
Source:	Journal of Medicinal Chemistry
ISSN:	0022-2623
Publisher:	American Chemical Society
Volume:	63
Number:	13
Page Range:	6834-6846
Date:	9 July 2020
Official Publication:	https://doi.org/10.1021/acs.jmedchem.0c00208
PubMed:	View item in PubMed

Repository Staff Only: item control page